Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06047080 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
A Phase 3 study of Large B-cell Lymphoma, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 1,130
- Enrollment target
- 20
- Study locations
NCT06047080: Active Phase 3 study of Large B-cell Lymphoma, sponsored by Hoffmann-La Roche.
NCT06047080 is a Phase 3 study of Large B-cell Lymphoma that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 1,130 participants, above the 119-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (850% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06047080, a Phase 3 study of Large B-cell Lymphoma, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,130 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Glofitamab
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Polatuzumab vedotin
Study Locations (20)
California
- Kaiser Permanente - Anaheim (E. La Palma) - Anaheim
- University of California, San Francisco-Fresno - Clovis
- City of Hope National Medical Center - Duarte
- City of Hope - Lennar Foundation Cancer Center - Irvine
- Valkyrie Clinical Trials - Los Angeles
- UCLA Jonsson Comprehensive Cancer Center - Los Angeles
- Kaiser Permanente - Roseville - Roseville
- Kaiser Permanente - Santa Clara - Santa Clara
- Stanford Univ School of Med - Stanford
- Kaiser Permanente Medical Ctr - Vallejo
Colorado
- University of Colorado Cancer Center - Aurora
- Rocky Mountain Cancer Center - Denver - Littleton
Florida
- Miami Cancer Institute of Baptist Health, Inc. - Miami
- Memorial Cancer Institute at Memorial West - Pembroke Pines
Illinois
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago
- Illinois Cancer Care - Peoria
Alaska
- Alaska Oncology & Hematology, LLC - Anchorage
Connecticut
- Yale University School Of Medicine - New Haven
District of Columbia
- Medstar Franklin Square Medical Center - Washington D.C.
Hawaii
- Hawaii Cancer Care - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,130 participants |
| Start Date | 2023-09-18 |
| Est. Completion | 2030-10-30 |
| Phase | Phase 3 |
What the registry record for NCT06047080 still lists
NCT06047080 is an interventional study that assigns participants to a tested intervention. Its 1,130 participants enrollment target places it among the larger protocols in the corpus, above the 119-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (850% higher).
The record links to 1 condition, with Large B-cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06047080 names 20 study sites across 8 states, led by California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT06047080 about?
NCT06047080 is a clinical study titled "An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma". The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
What is the current status of trial NCT06047080?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,130 participants. The study started on 2023-09-18. Estimated completion is 2030-10-30.
What conditions does trial NCT06047080 study?
This clinical trial studies the following conditions: Large B-cell Lymphoma.
What interventions are being tested in trial NCT06047080?
The interventions under investigation include: Cyclophosphamide (DRUG), Glofitamab (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Polatuzumab vedotin (DRUG).
Who is sponsoring clinical trial NCT06047080?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06047080 being conducted?
This trial has 20 study locations across Alaska, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06047080's enrollment target sits among peer trials
1,130 1st of 28 higher than 28 of 28 other Large B-cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Large B-cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RECRUITING · Phase 3
-
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06445062 · 1,130 participants · Phase 1
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- NCT06746129 · 1,126 participants · Phase 3
Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos
- NCT04421768 · 1,125 participants · NA
Effects of Systematic Cervical Exam Training on Labor and Delivery Care
- NCT06895148 · 1,125 participants · NA
ADHERE-LPV Advancing Delivery of High-Quality Evidence-Based Respiratory Efforts in Lung-Protective Ventilation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI